This is a Phase 4, multicenter, open-label study designed to characterize the pharmacokinetic (PK) profile of total bupivacaine in approximately 15 adult subjects undergoing primary unilateral total knee arthroplasty (TKA) with bupivacaine hydrochloride (HCl) spinal nerve block (SNB) and EXPAREL local infiltration into the surgical site.
On Day 1, following an epinephrine "wash" of the spinal block syringe, eligible subjects will receive a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure as a spinal block. EXPAREL 266 mg in 20 mL (expanded with 70 mL of preservative-free sterile normal saline to a total volume of 90 mL) will be infiltrated into the surgical site at the end of the surgery prior to wound closure. There will be no local co-administration of the two drugs. Blood samples for bupivacaine PK analysis will be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, and 72 hours after the beginning of EXPAREL administration, and on Day 14.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
Shaols Medical Trials, Inc.
Sheffield, Alabama, United States
University of Minnesota Medical Center - Fairview, West Bank
Minneapolis, Minnesota, United States
Maximum Plasma Concentration (Cmax)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
Time to Peak Plasma Concentration (Tmax)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Collection Time After Drug Administration (AUC0-last)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity After Drug Administration (AUC0-∞)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
The Apparent Terminal Elimination Rate Constant (λz)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
The Apparent Terminal Elimination Half-life (t1/2el)
Time frame: baseline, 15,30 min, 1,2,4,8,12,24,48,72 hours post dose, day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.